DR6 Stock Overview
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for DR6 from our risk checks.
ACADIA Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.29 |
| 52 Week High | US$29.40 |
| 52 Week Low | US$15.29 |
| Beta | 0.39 |
| 1 Month Change | -6.20% |
| 3 Month Change | -38.35% |
| 1 Year Change | -16.45% |
| 3 Year Change | -12.03% |
| 5 Year Change | -26.22% |
| Change since IPO | 180.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| DR6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.6% | -0.2% | 0.5% |
| 1Y | -16.4% | -22.8% | 1.3% |
Price Volatility
| DR6 volatility | |
|---|---|
| DR6 Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DR6's share price has been volatile over the past 3 months.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 598 | Steve Davis | www.acadia.com |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.
ACADIA Pharmaceuticals Inc. Fundamentals Summary
| DR6 fundamental statistics | |
|---|---|
| Market cap | €2.55b |
| Earnings (TTM) | -€57.13m |
| Revenue (TTM) | €677.18m |
3.7x
P/S Ratio-43.9x
P/E RatioIs DR6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DR6 income statement (TTM) | |
|---|---|
| Revenue | US$726.44m |
| Cost of Revenue | US$393.26m |
| Gross Profit | US$333.18m |
| Other Expenses | US$394.47m |
| Earnings | -US$61.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 45.87% |
| Net Profit Margin | -8.44% |
| Debt/Equity Ratio | 0% |
How did DR6 perform over the long term?
See historical performance and comparison